Express Scripts Holding Company Company Profile (NASDAQ:ESRX)

Express Scripts Holding Company trades on the NASDAQ under the ticker symbol "ESRX."

Express Scripts Holding Company (NASDAQ:ESRX) issued its earnings results on Tuesday, July, 25th. The company reported $1.73 EPS for the quarter, beating the Zacks' consensus estimate of $1.71 by $0.02. The company earned $25.35 billion during the quarter, compared to the consensus estimate of $25.52 billion. Express Scripts Holding Company had a return on equity of 25.58% and a net margin of 3.50%. Express Scripts Holding Company's quarterly revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.57 earnings per share. View Express Scripts Holding Company's Earnings History.

Express Scripts Holding Company is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Express Scripts Holding Company.

Express Scripts Holding Company updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share (EPS) guidance of $6.95-7.05 for the period, compared to the Thomson Reuters consensus estimate of $6.97. Express Scripts Holding Company also updated its Q3 guidance to $1.88-1.92 EPS.

20 brokers have issued twelve-month price objectives for Express Scripts Holding Company's shares. Their forecasts range from $56.00 to $85.00. On average, they anticipate Express Scripts Holding Company's share price to reach $68.50 in the next year. View Analyst Ratings for Express Scripts Holding Company.

Here are some recent quotes from research analysts about Express Scripts Holding Company stock:

• 1. According to Zacks Investment Research, "We are upbeat about Express Scripts’ pharmacy-benefits management long-term outlook. The projection takes the volatile healthcare market trends, inflation, patent expiration and lower industry utilization growth into consideration. Furthermore, Express Scripts should benefit from increased generic utilization, shift toward mail orders, strong specialty growth and an aging population. Branded drugs are becoming increasingly expensive due to double-digit brand inflation. Thus, continued rise in the price of specialty drugs and overwhelming regulatory burden is opening up considerable prospects for generics. However, over the past one year, Express Scripts has underperformed the broader industry in terms of price. Tough competition in the niche space and the persistent drug pricing issue are anticipated to affect the stock." (10/16/2017)
• 2. Jefferies Group LLC analysts commented, "We believe ESRX remains a Buy given our view that company fundamentals, including its FCF, are stable and that the stock's valuation is attractive at 9x FY18 P/E. That said, we recognize that headlines surrounding drug pricing pressure and the overhang from ESRX's Anthem contract will drive continued stock volatility NT." (2/17/2017)

Express Scripts Holding Company saw a increase in short interest in September. As of September 29th, there was short interest totalling 32,966,022 shares, an increase of 3.9% from the September 15th total of 34,319,116 shares. Based on an average trading volume of 3,654,812 shares, the days-to-cover ratio is currently 9.0 days. Approximately 5.7% of the company's shares are sold short.

Some companies that are related to Express Scripts Holding Company include Allergan PLC. (AGN), Stryker Corporation (SYK), Aetna (AET), Anthem (ANTM), Becton, Dickinson and Company (BDX), Fresenius SE (FSNUY), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), Shire PLC (SHPG), Intuitive Surgical (ISRG), Boston Scientific Corporation (BSX), Vertex Pharmaceuticals Incorporated (VRTX), Humana (HUM), Baxter International (BAX), Zoetis (ZTS), McKesson Corporation (MCK), Alexion Pharmaceuticals (ALXN) and Illumina (ILMN).

Express Scripts Holding Company's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include PGGM Investments (0.18%), Fisher Asset Management LLC (0.06%), Robeco Institutional Asset Management B.V. (0.06%), Shell Asset Management Co. (0.03%), Mutual of America Capital Management LLC (0.01%) and Bridges Investment Management Inc. (0.01%). Company insiders that own Express Scripts Holding Company stock include Christopher A Mcginnis, Everett Neville, Mahon Thomas P Mac, Phyllis S Anderson and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts Holding Company.

Express Scripts Holding Company's stock was sold by a variety of institutional investors in the last quarter, including Bridges Investment Counsel Inc., Assenagon Asset Management S.A., First National Bank of Mount Dora Trust Investment Services, Bridges Investment Management Inc., Quantitative Systematic Strategies LLC, Norway Savings Bank and Mutual of America Capital Management LLC. Company insiders that have sold Express Scripts Holding Company stock in the last year include Everett Neville, Phyllis S Anderson and Woodrow A Myers Jr. View Insider Buying and Selling for Express Scripts Holding Company.

Express Scripts Holding Company's stock was bought by a variety of institutional investors in the last quarter, including PGGM Investments, Shell Asset Management Co., Robeco Institutional Asset Management B.V., Fisher Asset Management LLC, BerganKDV Wealth Management LLC, Eqis Capital Management Inc., Balasa Dinverno & Foltz LLC and Summit X LLC. View Insider Buying and Selling for Express Scripts Holding Company.

Shares of Express Scripts Holding Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Express Scripts Holding Company stock can currently be purchased for approximately $59.51.